Representing individuals who took gabapentin (Neurontin) or pregabalin (Lyrica) and experienced early-onset dementia or cognitive impairments
Plaintiff(s):
Patients who were prescribed gabapentin or pregabalin 6 or more times between 2000 and 2024 for any purpose other than to treat nerve pain or seizures, and were diagnosed by a neurologist or other specialist with early-onset dementia before age 65
Case type / claims:
Lawsuits alleging that Pfizer and other manufacturers of gabapentin and pregabalin marketed the drugs for off-label, unapproved uses, and failed to warn consumers and their doctors about the risks associated with the drug.
Defendant(s):
Pfizer, Greenstone, Pharmacia & Upjohn, and others
Jurisdiction:
Cases being filed in state and federal courts across the United States
Year:
Active
Outcome:
- Active; plaintiffs are filing claims
- Principal Adam Gomez named plaintiffs liaison counsel in the litigation
